NASDAQ: TPSTTempest Therapeutics Inc Stock
$3.44+0.02 (+0.58%)
Updated Apr 24, 2024
TPST Price
$3.44
Fair Value Price
$1.20
Market Cap
$76.34M
52 Week Low
$0.17
52 Week High
$9.77
P/E
-1.8x
P/B
2.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.93
Operating Cash Flow
-$27M
Beta
1.54
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TPST Overview
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TPST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TPST ($3.44) is overvalued by 185.59% relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TPST ($3.44) is not significantly undervalued (185.59%) relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TPST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TPST due diligence checks available for Premium users.
Be the first to know about important TPST news, forecast changes, insider trades & much more!
TPST News
Valuation
TPST fair value
Fair Value of TPST stock based on Discounted Cash Flow (DCF)
Price
$3.44
Fair Value
$1.20
Overvalued by
185.59%
TPST ($3.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TPST ($3.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TPST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TPST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.8x
Industry
15.69x
Market
41.27x
TPST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.85x
Industry
5.86x
TPST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TPST's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
TPST's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$51.6M
Liabilities
$24.8M
Debt to equity
0.93
TPST's short-term assets ($40.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TPST's short-term assets ($40.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TPST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TPST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$7.0k
Financing
$34.3M
TPST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TPST vs Biotech Stocks
Tempest Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.